[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604426":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":34,"locations":41,"responsibleParty":75,"collaborators":77,"id":81,"slug":39,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":39,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":39,"enrollmentInfo":88,"targetDuration":39,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":39,"overallStatus":44,"whyStopped":39,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Alliance Foundation Trials, LLC.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Durvalumab and one of the two chemotherapy combinations: cisplatin or carboplatin, and etoposide","EXPERIMENTAL","65 participants will be enrolled.",[13],"Drug: Durvalumab 50 MG\u002FML",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Durvalumab 50 MG\u002FML","Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg\u002Fm2 or carboplatin AUC 5 on day 1, and etoposide 100 mg\u002Fm2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).",[9],[21,22],"Imfinzi®","MEDI4736",[24,28,31],{"name":25,"affiliation":26,"role":27},"Chi-Fu Jeffrey Yang, MD","Massachusetts General Hospital","STUDY_CHAIR",{"name":29,"affiliation":30,"role":27},"Jacob Sands, MD","Dana-Farber Cancer Institute",{"name":32,"affiliation":5,"role":33},"Evanthia Galanis, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Quality Management and Compliance","CONTACT","617-732-8727",null,"ClinicalTrials.Queries@alliancefoundationtrials.org",[42,55,65],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":39},"University of Illinois Chicago","RECRUITING","Chicago","Illinois","60612","United States",{"type":50,"coordinates":51},"Point",[52,53],-87.65005,41.85003,{"lat":53,"lon":52},{"facility":56,"status":44,"city":57,"state":58,"zip":59,"country":48,"cosmosGeoPoint":60,"geoPoint":64,"contacts":39},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":50,"coordinates":61},[62,63],-71.05977,42.35843,{"lat":63,"lon":62},{"facility":66,"status":44,"city":67,"state":68,"zip":69,"country":48,"cosmosGeoPoint":70,"geoPoint":74,"contacts":39},"University of Virginia Comprehensive Cancer Center","Charlottesville","Virginia","22908",{"type":50,"coordinates":71},[72,73],-78.47668,38.02931,{"lat":73,"lon":72},{"type":76,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[78],{"name":79,"class":80},"AstraZeneca","INDUSTRY","100604426",false,"NCT07149363","Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body weight \\>30 kg.\n* Must have a life expectancy of at least 12 weeks.\n* Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.\n* Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.\n* Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.\n* No prior systemic therapies, for small cell lung cancer.\n* Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agents.\n* Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.\n* Prior treatment with durvalumab.\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Superficial bladder cancer without active disease after treatment.\n  * Low grade prostate cancer without indication for active treatment.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.\n* Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.\n* Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.","ALL","18 Years",{"count":89,"type":90},65,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).",[96],"Small Cell Lung Cancer (SCLC)","2026-06-25",{"date":99,"type":100},"2026-06-26","ACTUAL",{"date":102,"type":100},"2026-02-12",{"date":104,"type":90},"2031-02",{"name":5,"class":6},3]